Telomir Pharmaceuticals, Inc. Travel and Entertainment Expense
Telomir Pharmaceuticals, Inc. (TELO) reported Travel and Entertainment Expense of $370.50 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:TravelAndEntertainmentExpense · last filed 2026-03-17
- Telomir Pharmaceuticals, Inc. travel and entertainment expense for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Telomir Pharmaceuticals, Inc. travel and entertainment expense for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Telomir Pharmaceuticals, Inc. travel and entertainment expense for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Telomir Pharmaceuticals, Inc. travel and entertainment expense for the quarter ending 2024-03-31 was $370.50K.
- Telomir Pharmaceuticals, Inc. travel and entertainment expense for fiscal 2024 was $370.50K, a 79.04% decline from fiscal 2023.
- Telomir Pharmaceuticals, Inc. travel and entertainment expense for fiscal 2023 was $1.77M.
| Period end | Travel and Entertainment Expense 3 month | Travel and Entertainment Expense 6 month | Travel and Entertainment Expense 9 month | Travel and Entertainment Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $370.50K 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $370.50K 10-Q · filed 2025-11-10 | $850.05K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $370.50K 10-Q · filed 2025-08-14 | $850.05K derived: sum of 3 quarters · filed 2025-08-14 | $1.44M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $370.50K 10-Q · filed 2025-05-14 | $850.05K derived: sum of 2 quarters · filed 2025-05-14 | $1.44M derived: sum of 3 quarters · filed 2025-05-14 | $2.14M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $479.55K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | $1.07M derived: sum of 2 quarters · filed 2025-02-04 | $1.77M derived: sum of 3 quarters · filed 2025-02-04 | $1.77M 10-K · filed 2025-02-04 |
| 2023-09-30 | $589.40K 10-Q · filed 2024-11-12 | $1.29M derived: sum of 2 quarters · filed 2024-11-12 | $1.29M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $698.60K 10-Q · filed 2024-08-13 | $698.60K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |